N/A N=155 Adaptation Of An HPV Education Resource To Promote HPV Vaccination
HPV Vaccine · HPV
Primary: Part 1: HPV Vaccine Knowledge (Aim 1) — 10.10; 3.19 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
Lung Cancer, Non-Small Cell · Metastatic Squamous Cell Carcinoma · Metastatic Non-Squamous Cell Carcinoma
Primary: Safety/Tolerability of ADXS-503 Monotherapy in Part A and ADXS-503 With Pembrolizumab in Part B: Graded Per Comment Terminology Criteria for Adverse Events (CTCAE)…
N/A N=81 Telehealth Group Intervention for Perinatal Depressive Symptoms
Perinatal Depression
Primary: Change in Depressive Symptoms Over Time — 11.11; 10.52; 7.34; 7.69 units on a scale — p=0.612
Phase 3 N=131 Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
Relapsing Multiple Sclerorsis · Multiple Sclerosis, Primary Progressive
Primary: Change in Levels of NfL (Neurofilament Light) in CSF From Treatment Baseline to Post-Treatment With Ocrelizumab — -1232.97; -1169.13; -1008.13; -931.83 pg/mL
N/A N=49 Motor Imagery Intervention for Improving Gait and Cognition in the Elderly
Motor Activity
Primary: Change in Walking Speed During Single and Dual-task Walking Conditions — -3.33; -0.53; 5.89; -10.55 centimeters per second
Phase 2 N=102 A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD
Treatment Resistant Depression
Primary: Montgomery Asberg Depression Rating Scale (MADRS) 24 Hours — -13.7; -15.3; -13.7 score on a scale
N/A N=99 Testing Brief Personalized Feedback Integrating EMA Alcohol Cue Information
Alcohol Drinking · Problem Drinking
Primary: Daily Drinking Questionnaire — 12.23; 11.78; 10.31; 9.40 Drinks per week — p=0.68
Phase 2 N=739 Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants
Rheumatoid Arthritis
Primary: Number of Participants Experiencing Treatment-Emergent Adverse Events — 453; 223 participants
N/A N=60 A Text-Based Adherence Game for Young People Living With HIV in Ghana
HIV/AIDS · Medication Adherence
Primary: HIV-1 Viral Load (log10 Transformed) — 2.22; 2.18 log10 HIV copies/mL — p=<0.05
N/A N=405 Comparative Effectiveness of Social Physical Play and Traditional Exercise Programming
Group Fitness (Traditional) · Group Fitness (Game Play-based)
Primary: Session Attendance — 12.3; 10.4 Percentage of possible sessions attended
N/A N=145 Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada
Sickle Cell Disease · Sickle Cell Trait · Beta-Thalassemia
Primary: Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value — 96.6; 100; 0; 91.3 percentage
N/A N=10 Effect of Ultrasound Guided Laser Ablation Therapy on Symptomatic Benign Thyroid Nodules
Thyroid Nodule
Primary: Change in Radiographic Volume of Thyroid Nodule From Baseline at 3, 6 and 12 Months After Laser Ablation — 63.4; 71.087 percentage of volume reduction
N/A N=71 Xenodiagnosis After Antibiotic Treatment for Lyme Disease
Lyme Disease
Primary: Detection of Borrelia Burgdorferi in Ticks After Xenodiagnosis Procedure — 1; 0; 418; 319 Ticks
Phase 1 N=24 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease
Gastroesophageal Reflux
Primary: Maximum Observed Drug Concentration at Steady State (Cmax-ss) of Vonoprazan — 13.4; 26.7 ng/mL
N/A N=173 PET Scan in Treating Patients With Metastatic Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 91.6 weeks